复星医药(600196)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
中信证券 2026-04-08 买入
中国银河 2026-03-25 买入
天风证券 2026-01-27 买入
  盈利预测
据复星医药四季报分析:

  盈利能力有所削弱,总资产收益能力略有提升

  成长能力有所加强,营利增速有所收窄,盈利性受挤压

  偿债能力维持稳定,盈利增速略高于债务增速

  运营能力维持稳定,流动资产得到了合理利用

  现金流能力维持稳定,销售回款能力有所减弱

  财务数据
2025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
每股收益(元)1.270.950.640.291.040.750.460.23
每股净资产(元)18.2517.9917.7517.9417.6917.7117.5717.34
每股资本公积金(元)6.136.126.106.246.216.566.576.30
每股未分配利润(元)10.8810.5710.2710.239.949.679.379.41
每股经营性现金流(元)1.951.270.800.401.681.120.710.34
净资产收益率(%)7.035.303.581.615.904.322.661.33
营业总收入(元)416.62亿293.93亿195.14亿94.20亿410.67亿309.12亿204.63亿101.57亿
营业总收入同比增长(%)1.45-4.91-4.63-7.26-0.800.69-4.36-6.56
归属净利润(元)33.71亿25.23亿17.02亿7.65亿27.70亿20.11亿12.25亿6.10亿
归属净利润同比增长(%)21.6925.5038.9625.4216.08-11.93-31.09-38.22
扣非净利润(元)23.40亿15.73亿9.61亿4.10亿23.14亿18.36亿12.54亿6.09亿
扣非净利润同比增长(%)1.12-14.32-23.39-32.5615.1024.58-8.64-33.81
毛利率(%)50.0748.2048.1247.7747.9748.6048.8750.01
净利率(%)10.2010.4010.7610.008.558.157.577.74
资产负债率(%)48.4948.5249.2448.4348.9848.6449.0549.42
存货周转率(次)3.022.131.420.692.842.091.370.67
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点
  • 总资产(亿元)
  • 负债(亿元)
    截至2025年年度最新总资产12005396.89万元,负债5821361.91万元。

利润表
报告期2025-12-312025-09-302025-06-302025-03-31
营业总收入41,661,612,748.1529,393,385,360.9119,514,431,849.599,420,322,797.34
营业总成本40,087,325,053.4928,415,595,587.618,904,362,502.049,130,342,151.68
其他经营收益
营业利润5,228,351,339.593,906,765,379.572,761,208,390.861,358,771,228.34
利润总额5,111,983,263.873,837,343,481.792,718,481,583.081,347,541,972.01
净利润4,247,929,628.383,056,091,951.682,100,210,564.8941,566,276.85
每股收益
其他综合收益-675,759,872.93-385,229,723.22-32,659,264.99-110,471,546.95
综合收益总额3,572,169,755.452,670,862,228.462,067,551,299.81831,094,729.9
资产负债表
报告期2025-12-312025-09-302025-06-302025-03-31
流动资产:
流动资产合计33,820,671,330.2732,145,481,005.8834,342,267,603.1934,438,609,708.93
非流动资产:
非流动资产合计86,233,297,595.7885,975,257,507.1384,485,669,451.9183,551,879,181.16
资产总计120,053,968,926.05118,120,738,513.01118,827,937,055.1117,990,488,890.09
流动负债:
流动负债合计36,424,316,078.8435,086,945,012.2236,023,336,557.9735,500,536,915.25
非流动负债:
非流动负债合计21,789,302,995.8722,222,193,608.3222,489,492,119.0321,640,050,046.76
负债合计58,213,619,074.7157,309,138,620.5458,512,828,67757,140,586,962.01
所有者权益(或股东权益):
归属于母公司股东权益合计48,741,507,004.748,028,502,901.0547,397,623,662.6747,923,631,569.95
股东权益合计61,840,349,851.3460,811,599,892.4760,315,108,378.160,849,901,928.08
负债和股东权益合计120,053,968,926.05118,120,738,513.01118,827,937,055.1117,990,488,890.09
现金流量表
报告期2025-12-312025-09-302025-06-302025-03-31
经营活动产生的现金流量:
经营活动现金流入小计43,315,418,661.3432,212,081,100.7421,388,993,511.9610,431,224,855.47
经营活动现金流出小计38,102,191,782.9928,830,312,535.0319,254,993,017.659,375,544,977.02
经营活动产生的现金流量净额5,213,226,878.353,381,768,565.712,134,000,494.311,055,679,878.45
投资活动产生的现金流量:
投资活动现金流入小计3,722,258,666.042,888,011,838.782,012,663,450.931,275,324,161.38
投资活动现金流出小计5,868,024,954.774,399,844,279.572,872,400,465.891,460,415,546.78
投资活动产生的现金流量净额-2,145,766,288.73-1,511,832,440.79-859,737,014.96-185,091,385.4
筹资活动产生的现金流量:
筹资活动现金流入小计37,334,019,380.1526,869,314,775.6616,848,567,870.256,711,769,738.58
筹资活动现金流出小计40,578,108,887.330,113,741,396.8518,308,768,144.077,345,397,027.42
筹资活动产生的现金流量净额-3,244,089,507.15-3,244,426,621.19-1,460,200,273.82-633,627,288.84
汇率变动对现金及现金等价物的影响-176,810,748.88-80,826,833.379,762,529.48,912,313.03
现金及现金等价物净增加额-353,439,666.41-1,455,317,329.64-176,174,265.07245,873,517.24
期末现金及现金等价物余额9,038,010,120.77,936,132,457.479,215,275,522.049,637,323,304.35
补充资料:
现金及现金等价物的净增加额-353,439,666.41--176,174,265.07-
  十大流通股东
  • 总资产(亿元)
  • 负债(亿元)
    截至2025年年度最新总资产12005396.89万元,负债5821361.91万元。

利润表
报告期2025-12-312025-09-302025-06-302025-03-31
营业总收入41,661,612,748.1529,393,385,360.9119,514,431,849.599,420,322,797.34
营业总成本40,087,325,053.4928,415,595,587.618,904,362,502.049,130,342,151.68
其他经营收益
营业利润5,228,351,339.593,906,765,379.572,761,208,390.861,358,771,228.34
利润总额5,111,983,263.873,837,343,481.792,718,481,583.081,347,541,972.01
净利润4,247,929,628.383,056,091,951.682,100,210,564.8941,566,276.85
每股收益
其他综合收益-675,759,872.93-385,229,723.22-32,659,264.99-110,471,546.95
综合收益总额3,572,169,755.452,670,862,228.462,067,551,299.81831,094,729.9
资产负债表
报告期2025-12-312025-09-302025-06-302025-03-31
流动资产:
流动资产合计33,820,671,330.2732,145,481,005.8834,342,267,603.1934,438,609,708.93
非流动资产:
非流动资产合计86,233,297,595.7885,975,257,507.1384,485,669,451.9183,551,879,181.16
资产总计120,053,968,926.05118,120,738,513.01118,827,937,055.1117,990,488,890.09
流动负债:
流动负债合计36,424,316,078.8435,086,945,012.2236,023,336,557.9735,500,536,915.25
非流动负债:
非流动负债合计21,789,302,995.8722,222,193,608.3222,489,492,119.0321,640,050,046.76
负债合计58,213,619,074.7157,309,138,620.5458,512,828,67757,140,586,962.01
所有者权益(或股东权益):
归属于母公司股东权益合计48,741,507,004.748,028,502,901.0547,397,623,662.6747,923,631,569.95
股东权益合计61,840,349,851.3460,811,599,892.4760,315,108,378.160,849,901,928.08
负债和股东权益合计120,053,968,926.05118,120,738,513.01118,827,937,055.1117,990,488,890.09
现金流量表
报告期2025-12-312025-09-302025-06-302025-03-31
经营活动产生的现金流量:
经营活动现金流入小计43,315,418,661.3432,212,081,100.7421,388,993,511.9610,431,224,855.47
经营活动现金流出小计38,102,191,782.9928,830,312,535.0319,254,993,017.659,375,544,977.02
经营活动产生的现金流量净额5,213,226,878.353,381,768,565.712,134,000,494.311,055,679,878.45
投资活动产生的现金流量:
投资活动现金流入小计3,722,258,666.042,888,011,838.782,012,663,450.931,275,324,161.38
投资活动现金流出小计5,868,024,954.774,399,844,279.572,872,400,465.891,460,415,546.78
投资活动产生的现金流量净额-2,145,766,288.73-1,511,832,440.79-859,737,014.96-185,091,385.4
筹资活动产生的现金流量:
筹资活动现金流入小计37,334,019,380.1526,869,314,775.6616,848,567,870.256,711,769,738.58
筹资活动现金流出小计40,578,108,887.330,113,741,396.8518,308,768,144.077,345,397,027.42
筹资活动产生的现金流量净额-3,244,089,507.15-3,244,426,621.19-1,460,200,273.82-633,627,288.84
汇率变动对现金及现金等价物的影响-176,810,748.88-80,826,833.379,762,529.48,912,313.03
现金及现金等价物净增加额-353,439,666.41-1,455,317,329.64-176,174,265.07245,873,517.24
期末现金及现金等价物余额9,038,010,120.77,936,132,457.479,215,275,522.049,637,323,304.35
补充资料:
现金及现金等价物的净增加额-353,439,666.41--176,174,265.07-
  主力控盘
  公司简介
复星医药 所属地域: 上海市 涉及概念: 阿尔茨海默概念,AI智能体,DeepSeek概念,智能医疗,减肥药,创新药,机器人概念,猴痘概念,家庭医生,辅助生殖,新冠检测,医美概念,生物疫苗,仿制药一致性评价,MSCI预期,医疗器械概念,细胞免疫治疗,证金持股,青蒿素,流感,沪股通,民营医院,融资融券,医疗改革
主营业务: 生物化学产品,试剂,生物四技服务,生产销售自身开发的产品,仪器仪表,电子产品,计算机,化工原料(除危险品),咨询服务;经营本企业自产产品及相关技术的出口业务,经营本企业生产、科研所需的原辅材料、机械设备、仪器仪表、零配件及相关技术的进口业务。【依法须经批准的项目,经相关部门批准后方可开展经营活动】
上市日期: 1998-08-07 每股净资产: 18.25元 每股收益: 1.27元 净利润: 33.71亿元 净利润增长率: 21.69%
营业收入: 416.62亿元 每股现金流: 1.95元 每股公积金: 6.13元 每股未分配利润: 10.88元 总股本: 26.70亿 流通股: 21.18亿



以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心